In October 2022, China Merchants China Direct (CMCDI, 133 HK) Investments invested US$ 8m in Immvira Bioscience (亦諾微醫藥), a biotech R&D firm that develops cancer treatment.

Immvira Bioscience has just filed with HKEx to go IPO.

CMCDI now owns 1.65% stake in Immvira, and is marking the position at US $5m, or 0.64% of CMCDI’s total assets.

Good luck.

💬 WeChat: ASM_Argyle

💬 WhatsApp: +852 6317 6371

🖥️ UnlockValueChinaMerchants.com

📧 ChinaMerchants@asmhk.com


2022年10月,招商局中國基金(133 HK)向亦諾微醫藥(Immvira Bioscience)投資800萬美元。亦諾微醫藥是一家專注於癌症治療的生物技術研發公司。

亦諾微醫藥剛剛向香港交易所提交了IPO申請。

招商局中國基金目前持有亦諾微醫藥1.65%的股份,並將該持股估值為500萬美元,占招商局中國基金總資產的0.64%。

💬 WeChat: ASM_Argyle

💬 WhatsApp: +852 6317 6371

🖥️ UnlockValueChinaMerchants.com

📧 ChinaMerchants@asmhk.com

Leave a comment